昆药集团：短期业绩承压，银发经济长期发展向好-20260324

Investment Rating - The investment rating for Kunming Pharmaceutical Group is "Buy" (maintained) [1] Core Views - The company's short-term performance is under pressure, but the long-term development prospects in the silver economy are positive [1] - The company faced significant challenges in 2025, with total revenue declining by 21.74% year-on-year to 6.575 billion yuan and net profit attributable to shareholders dropping by 46% to 349.94 million yuan [8] - The decline in performance is attributed to delayed execution of centralized procurement in hospitals, ongoing cost control in medical insurance, and competitive pressures in existing businesses [8] - The company is actively participating in national and provincial centralized procurement, enhancing its coverage in hospital and grassroots terminals, and focusing on academic promotion and team collaboration [8] - Brand building is emphasized, with a focus on the silver health industry and premium traditional Chinese medicine, aiming to create a competitive moat [8] Financial Summary - Total revenue forecast for 2025 is 6.575 billion yuan, with a projected decline of 21.74% [1] - Net profit attributable to shareholders is forecasted to be 349.94 million yuan in 2025, down 46% year-on-year [1] - Earnings per share (EPS) is expected to be 0.46 yuan in 2025, with a P/E ratio of 24.27 [1] - The company anticipates a gradual recovery in core products as centralized procurement policies are implemented [8] - Long-term growth is supported by strategic investments in brand and market expansion, particularly in the aging population and premium traditional Chinese medicine sectors [8]